Opinion/decision on a Paediatric investigation plan (PIP): Prevenar 20 (previously Apexxnar), Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Vaccines, PIP number: P/0246/2023

Human medicines European public assessment report (EPAR): Sirturo, bedaquiline, Date of authorisation: 05/03/2014, Revision: 22, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Camzyos, Mavacamten, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Cardiovascular diseases, PIP number: P/0278/2023

Opinion/decision on a Paediatric investigation plan (PIP): Xospata, Gilteritinib (as fumarate), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Haematology-Hemostaseology, PIP number: P/0267/2023

EMEA-001821-PIP01-15-M07

EMEA-001624-PIP01-14-M06

Opinion/decision on a Paediatric investigation plan (PIP): Natpar, Recombinant parathyroid hormone, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Endocrinology-Gynaecology-Fertility-Metabolism, PIP number: P/0276/2023

Human medicines European public assessment report (EPAR): Cayston, aztreonam, Date of authorisation: 21/09/2009, Revision: 21, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Rezolsta, darunavir,cobicistat, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0257/2023

Opinion/decision on a Paediatric investigation plan (PIP): Imlygic, talimogene laherparepvec, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0275/2023